Showing 4751-4760 of 5957 results for "".
- GenSight Biologics Announces Publication of Indirect Comparison Showing Treatment Effect of Lumevoq Versus Natural Historyhttps://modernod.com/news/gensight-biologics-announces-publication-of-indirect-comparison-showing-treatment-effect-of-lumevoq-versus-natural-history/2479249/GenSight Biologics announced that the journal Frontiers in Neurology has published results of the indirect comparison of the evolution of visual outcomes in patients treated with Lumevoq gene therapy with the spontaneous evolution in natural history (NH) studies of Leber hereditary optic
- iHealthScreen Announces CE Certification for iPredict Automated AI Systemhttps://modernod.com/news/ihealthscreen-announces-ce-mark-for-ipredict-automated-ai-system-for-early-diagnosis-of-dr-amd-and-glaucoma-suspect/2479244/iHealthScreen announced that it is the first company in the US to receive a CE certification for simultaneous diagnosis of diabetic retinopathy (DR), age related macular degeneration (AMD), and glaucoma suspect screening, according to a company news release. Using the iPredict System,
- Scientists: New Research May Revolutionize Cataract Treatmenthttps://modernod.com/news/scientists-new-research-may-revolutionize-cataract-treatment/2479235/Eye experts have made a breakthrough that could potentially change the way cataracts are treated – with potential for drug therapy to replace surgery. A team of international scientists, led by Professor Barbara Pierscionek of Anglia Ruskin University (ARU), has published
- Heru Series A Funding Accelerates Cloud and AI-Enabled Wearable Vision Diagnosis and Therapyhttps://modernod.com/news/heru-series-a-funding-accelerates-cloud-and-ai-enabled-wearable-vision-diagnosis-and-therapy/2479231/Heru, developer of wearable AI-powered vision diagnostics and augmentation software, closed its Series A financing of $30 million to advance the company’s eye diagnostic and vision correction technology platform. Originating as a spinout from Bascom Palmer Eye Institute, the Series A follo
- MedOne Surgical Receives FDA Clearance for its MicroDose Injectorhttps://modernod.com/news/medone-surgical-receives-fda-clearance-for-its-microdose-injector/2479227/MedOne Surgical announced the FDA 510(k) clearance of its MicroDose Injector device for low volume ophthalmic injections into the subretinal space. The pneumatically driven syringe system allows the surgeon to utilize a pneumatic air source, such as a vitrectomy system, to deliver a low volume in
- Bio-Techne and Narayana Nethralaya Collaborate On the Use of Ella for Ophthalmic Disorder Diagnostic Applicationshttps://modernod.com/news/bio-techne-and-narayana-nethralaya-collaborate-on-the-use-of-ella-for-ophthalmic-disorder-diagnostic-applications/2479224/Bio-Techne announced a collaboration with Narayana Nethralaya to develop a diagnostic solution for ophthalmology disorders on its ProteinSimple branded, multiplexing immunoassay instrument, Ella. The Ella platform, which is currently sold for research use only, allows users to perform high-qualit
- Alimera Sciences Appoints David Dyer, MD, as Chief Retina Specialisthttps://modernod.com/news/alimera-sciences-appoints-david-dyer-md-as-chief-retina-specialist/2479222/Alimera Sciences has announced the expansion of its leadership team with the appointment of David Dyer, MD, as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business exp
- Rayner Receives FDA Approval for RayOne Spheric Monofocal IOLhttps://modernod.com/news/rayner-receives-fda-approval-for-rayone-spheric-monofocal-iol/2479221/Rayner has received FDA approval for the RayOne Spheric fully-preloaded monofocal IOL. The approval marks Rayner’s third FDA approval in under 3 years within its RayOne preloaded IOL portfolio. RayOne Spheric joins RayOne Aspheric (FDA approved December 2018) and RayOne EMV, a new non-diffractive
- Three Companies Combine to Form Corza Medicalhttps://modernod.com/news/three-companies-combine-to-form-corza-medical/2479217/Corza Medical, a provider of surgical products and technologies, was formed after uniting Surgical Specialties Corporation, Caliber Ophthalmics, and the TachoSil hemostatic patch device. &
- Biogen’s Phase 2/3 Gene Therapy Study for XLRP Fails to Meet Primary Endpointhttps://modernod.com/news/biogens-phase-2-3-gene-therapy-study-for-xlrp-fails-to-meet-primary-endpoint/2479216/Biogen announced topline results from the phase 2/3 XIRIUS study of cotoretigene toliparvovec (BIIB112), a gene therapy being investigated as a one-time therapy for patients with X-linked retinitis pigmentosa (XLRP). The XIRIUS study did not meet its primary endpoint of demonstrating a st